Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?
American Journal of Psychiatry · 01.03.2025 · 182 (3) · 247-258
DOI: 10.1176/appi.ajp.20240378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Psychiatry, erschienen am 01.03.2025. Verfasst von Marjorie R Levinstein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biobehavioral Imaging and Molecular Neuropsychopharmacology Section, NIDA, Baltimore (Levinstein, Budinich, Michaelides); Department of Pathology and…. Hauptthemen laut MEDLINE: Depression, Ketamine, Receptors, N-Methyl-D-Aspartate, Antidepressive Agents. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders such as anxiety, obsessive-compulsive, and opioid use disorders. Despite its complex pharmacology, ketamine is referred to as an N-methyl-d-aspartate (NMDA) receptor antagonist. In this review, the authors argue that ketamine's pharmacology should be redefined to include opioid receptors and the endogenous opioid system. They also highlight a potential mechanism of action of ketamine for depression that is attributed to bifunctional, synergistic interactions involving NMDA and opioid receptors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biobehavioral Imaging and Molecular Neuropsychopharmacology Section, NIDA, Baltimore (Levinstein, Budinich, Michaelides); Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of…
Förderung
- Intramural NIH HHS
Zitieren
APA
Levinstein, M. R., Budinich, R. C., Bonaventura, J., Schatzberg, A. F., Zarate, C. A., & Michaelides, M. (2025). Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?. American Journal of Psychiatry, 182(3), 247-258. https://doi.org/10.1176/appi.ajp.20240378
Vancouver
Levinstein MR, Budinich RC, Bonaventura J, Schatzberg AF, Zarate CA, Michaelides M. Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?. American Journal of Psychiatry. 2025;182(3):247-258. doi:10.1176/appi.ajp.20240378
BibTeX
@article{Levinstein2025,
author = {Levinstein, Marjorie R and Budinich, Reece C and Bonaventura, Jordi and Schatzberg, Alan F and Zarate, Carlos A and Michaelides, Michael},
title = {Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?},
journal = {American Journal of Psychiatry},
year = {2025},
volume = {182},
number = {3},
pages = {247--258},
doi = {10.1176/appi.ajp.20240378}
}
EUVIMED